United Therapeutics Corporation (UTHR) is set to present five presentations and one poster at the CHEST 2024 Annual Meeting, highlighting clinical data from its commercial and development portfolio, including new analyses from the BREEZE open-label extension study of Tyvaso DPI in patients with pulmonary arterial hypertension (PAH). The meeting, hosted by the American College of Chest Physicians, will take place October 6-9, 2024, in Boston.
Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics, stated, “The CHEST Annual Meeting remains an important event for United Therapeutics and the pulmonary hypertension community, and this year we are excited to share additional analyses, particularly from the BREEZE open-label extension study, that continue to expand on these important learnings.”
Key Presentations
Several rapid-fire original investigation presentations will cover a range of topics:
- Patient-Reported Symptom Burden and Health-Related Quality of Life in Pulmonary Arterial Hypertension: Results from a Patient’s Perspective on Palliative Care Online Survey, presented by Denise Sese, M.D., Medical University of South Carolina.
- Initial Validation of the Pulmonary Hypertension Functional Classification Self-Report (PH-FC-SR): A Patient Focused Measure for Use in Research and in the Clinic, presented by Kristin Highland, M.D., FCCP, Cleveland Clinic.
- Real-World Hospitalization Differences in Patients with Pulmonary Hypertension due to Interstitial Lung Disease: Initiating Inhaled Treprostinil vs. Those Who Remain Untreated, presented by Steven Cassady, M.D., University of Maryland Medical Center.
- Long-Term Outcomes and Dosing in the BREEZE Study Optional Extension Phase: Presented by Abubakr Bajwa, MBBS, FCCP, Mayo Clinic.
- Inhaled Treprostinil for the Treatment of Connective Tissue-Associated Pulmonary Arterial Hypertension: Presented by Kristin Highland, M.D., FCCP, Cleveland Clinic.
Poster Presentation
A poster discussion session will feature data on:
- Real-World Oral Treprostinil Initiations: Insights from Specialty Pharmacy Data, presented by Daniel Lachant, D.O., University of Rochester Medical Center.
Sponsored Events
United Therapeutics is also sponsoring several events, including:
- The APPs in Chest Medicine Forum: Featuring presentations on navigating opportunities and challenges APPs face in clinical practice.
- The Women in Chest Medicine Annual Luncheon: Highlighting negotiation skills and honoring the 2024 recipient of the CHEST Women’s Lung Health grant.
- Tyvaso DPI® (Treprostinil Inhalation Powder): Clinical Pearls and Drug-Device Characteristics: A symposium featuring experts discussing clinical insights and device characteristics.
About Tyvaso DPI
Tyvaso DPI (treprostinil) Inhalation Powder is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).
United Therapeutics continues to focus on innovating for unmet medical needs, with a public benefit purpose to provide a brighter future for patients through novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.
